New specific migraine prevention: monoclonal antibodies against calcitonin gene-related peptide and its receptor
Migraine is a long-lasting neurological disorder with significant negative impact not only on the patient’s life, but also on society. For many years, preventive treatment of migraine included drugs developed for diseases other than migraine such as hypertension, depression, and epilepsy. During th...
Saved in:
| Main Authors: | K. Ryliškienė, D. Jatužis, A. Vaitkus |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2019-12-01
|
| Series: | Neurologijos seminarai |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27765 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
by: Máté Héja, et al.
Published: (2025-04-01) -
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
by: Christian Lampl, et al.
Published: (2024-12-01) -
Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01) -
Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01)